As a secondary endpoint, we evaluated the relationship between these genetic variants and the concentration of the corresponding proteins in the synovial fluid and in the plasma, with a focus on PTX3, which we recently proposed as a novel marker of PJI. This evidence concerns the gene PTX3 and juvenile polyposis syndrome.